


FIGS. 1A-C



35.0
30.0
25.0
20.0
15.0
Mean eGFR ± SE (ml/min/1.73 m2)
PBO
BARD
0
8
16
24
32
40
48
Week

FIG. 2



70%
60%
50%
40%
30%
20%
10%
0%
Percentage of Patients
PBO
ΔeGFR < -3
ΔeGFR < -5
ΔeGFR < -7.5
67%
37%
16%
0
8
16
24
32
40
48
Treatment Week

FIG. 3A



70%
60%
50%
40%
30%
20%
10%
0%
Percentage of Patients
BARD
ΔeGFR < -3
ΔeGFR < -5
ΔeGFR < -7.5
20%
14%
8%
0
8
16
24
32
40
48
Treatment Week

FIG. 3B



Estimated Proportion of Patients with ESRD or CV Death by 90T
0.25
0.20
0.15
0.10
0.05
0.00
0 4 8 12 16 24 32 40 48 56 64
Weeks Since Randomization
No. at risk (ITT Population)
BARD —— 1088 1077 1060 962 904 756 571 429 297 137 16
PBO ----- 1097 1085 1076 1004 922 768 596 439 318 142 19

FIG. 4



Mean Serum Magnesium (mEq/L)
180
175
170
165
160
155
150
145
0
8
16
24
32
40
48
Weeks
Placebo
Bardoxolone Methyl

FIG. 5



8.0
4.0
0.0
-4.0
-8.0
PBO
BARD
Mean SBP Change ± SE (mmHg)
0
4
8
12
16
24
32
40
48
Treatment Week

FIG. 6A



5.0
3.0
1.0
-1.0
-3.0
-5.0
PBO
BARD
Mean DBP Change ±SE (mmHg)
0
4
8
12
16
24
32
40
48
Treatment Week

FIG. 6B



ABPM WK4 Mean SBP
Change ± SE (mmHg)
8.0
4.0
0.0
-4.0
-8.0
PBO (n = 71)
BARD (n = 66)
All
Day
Night

FIG. 7A



ABPM WK4 Mean DBP
Change ± SE (mmHg)
5.0
3.0
1.0
-1.0
-3.0
-5.0
PBO (n = 71)
BARD (n = 66)
All
Day
Night

FIG. 7B



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
20 mg BARD
90% CI

FIG. 8A



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
20 mg BARD
90% CI

FIG. 8B



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
80 mg BARD
90% CI

FIG. 8C



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
80 mg BARD
90% CI

FIG. 8D



20 mg BM
90% CI
ΔΔ QTcF (ms)
20
15
10
5
0
−5
−10
−15
0 2 4 6 8 10 12 14 16 18 20 22 24
Time (h)

FIG. 9A




80 mg BM
90% CI
ΔΔ QTcF (ms)
20
15
10
5
0
−5
−10
−15
0 2 4 6 8 10 12 14 16 18 20 22 24
Time (h)

FIG. 9B



Patients at risk (n)

25mg	455	206	141	106
50mg	478	213	130	96
Placebo	459	309	211	152

FIG. 10A




FIG. 10B



Estimated Proportion of Patients Hospitalized/Died of HF by SDT
0.25
0.20
0.15
0.10
0.05
0.00
0 4 8 12 16 24 32 40 48 56 64
Weeks Since Randomization
No. at risk (ITT Population)
BARO 1080 1045 1006 942 864 723 548 417 288 133 15
PBO 1097 1069 1070 924 907 762 591 436 315 135 20

FIG. 11



Estimated proportion of patients who died
0.25
0.20
0.15
0.10
0.05
0.00
0 4 8 12 16 24 32 40 48 56 64 72
Weeks Since Randomization
No. at risk (ITT Population)
BARD —— 1088 1082 1065 993 917 770 590 451 315 144 19 1
PLACEBO - - - - - 1087 1086 1061 1010 930 786 624 464 341 156 23 0

FIG. 12